Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series

Firas El Chaer, Nobuyoshi Mori, Dimpy P Shah, Nora Oliver, Emily Wang, Anna Jan, Vi Doan, Frank Tverdek, Jean Tayar, Ella Ariza-Heredia, Roy F. Chemaly

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

Original languageEnglish (US)
Pages (from-to)91-96
Number of pages6
JournalAntiviral Research
Volume135
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

leflunomide
Salvage Therapy
Cell Transplantation
Cytomegalovirus Infections
Cytomegalovirus
Drug Monitoring
Hematopoietic Stem Cells
Transplants
Therapeutic Uses
Complementary Therapies
Safety
Pharmaceutical Preparations

Keywords

  • Cytomegalovirus
  • Drug level
  • Leflunomide
  • Resistance
  • Stem cell transplant

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients : A case series. / El Chaer, Firas; Mori, Nobuyoshi; Shah, Dimpy P; Oliver, Nora; Wang, Emily; Jan, Anna; Doan, Vi; Tverdek, Frank; Tayar, Jean; Ariza-Heredia, Ella; Chemaly, Roy F.

In: Antiviral Research, Vol. 135, 01.11.2016, p. 91-96.

Research output: Contribution to journalArticle

El Chaer, Firas ; Mori, Nobuyoshi ; Shah, Dimpy P ; Oliver, Nora ; Wang, Emily ; Jan, Anna ; Doan, Vi ; Tverdek, Frank ; Tayar, Jean ; Ariza-Heredia, Ella ; Chemaly, Roy F. / Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients : A case series. In: Antiviral Research. 2016 ; Vol. 135. pp. 91-96.
@article{bf7f2ad4a1d3463f823c70ece334192b,
title = "Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series",
abstract = "Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.",
keywords = "Cytomegalovirus, Drug level, Leflunomide, Resistance, Stem cell transplant",
author = "{El Chaer}, Firas and Nobuyoshi Mori and Shah, {Dimpy P} and Nora Oliver and Emily Wang and Anna Jan and Vi Doan and Frank Tverdek and Jean Tayar and Ella Ariza-Heredia and Chemaly, {Roy F.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.antiviral.2016.08.027",
language = "English (US)",
volume = "135",
pages = "91--96",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients

T2 - A case series

AU - El Chaer, Firas

AU - Mori, Nobuyoshi

AU - Shah, Dimpy P

AU - Oliver, Nora

AU - Wang, Emily

AU - Jan, Anna

AU - Doan, Vi

AU - Tverdek, Frank

AU - Tayar, Jean

AU - Ariza-Heredia, Ella

AU - Chemaly, Roy F.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

AB - Cytomegalovirus (CMV) reactivation is a clinically significant complication in hematopoietic stem cell transplant (HCT) recipients. Alternative therapy for multidrug-resistant CMV is limited and often fails. Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking. In this report, we describe 3 HCT recipients with multi-drug resistant CMV infections who received leflunomide as adjuvant and salvage therapy. The therapeutic effect of leflunomide as an anti-CMV agent based on virologic responses and therapeutic drug monitoring were evaluated.

KW - Cytomegalovirus

KW - Drug level

KW - Leflunomide

KW - Resistance

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84991790351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991790351&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2016.08.027

DO - 10.1016/j.antiviral.2016.08.027

M3 - Article

C2 - 27594527

AN - SCOPUS:84991790351

VL - 135

SP - 91

EP - 96

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -